Brad Rovin, MD

Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, discuss the future of IgAN treatment, highlighting the BlyS/APRIL axis.

Drs Jonathan Barratt and Brad Rovin comment on clinical trial data regarding the use of povetacicept for the treatment of IgAN.

Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, review clinical trials for new and emerging treatments for IgAN, highlighting atacicept and telitacicept.

Nephrology experts explore the role of dual inhibition of BlyS and APRIL in the treatment of IgAN, and how this can impact disease pathogenesis.

Brad Rovin, MD, outlines the use of complement inhibitors as an alternative to systemic glucocorticoids for the treatment of IgAN.

Experts in nephrology focus on the need for an agent which inhibits the pathogenesis or interrupts disease progression of IgAN.

Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, provide an overview of the foundational therapies approved for treatment of IgAN and their functions.

Jonathan Barratt, PhD, FRCP, and Brad Rovin, MD, review the driving factors of disease progression of IgAN (immunoglobulin A nephropathy).